Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Primary Industries
- Cancer
- Drugs
- Biotechnology
- Diagnostic
- Disease
- Therapeutic
- Diagnostic Substances
- Medical
- Antibody
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27493
License Grant
The University hereby grants to Licensee the exclusive, worldwide license under the Licensed Patents to make, have made, use, market and sell Products; biological materials covering (i) the human mammary cell growth inhibitor protein known as mammastatin, the aene encodin, such protein, and methods of making and using same, Human Mammary ‘Cell Growth Inhibitor Protein and Mammastatin – A Mammary Cell Growth Inhibitor and (ii) monoclonal antibodies directed against the protein known as mammastatin, and methods of making and using same, Monoclonal Anti-bodies to Human Mammary Cell Growth Inhibitor.
License Property
'Mammastatin' means a protein produced by the normal mammary gland (breast) in humans that controls the growth of breast cancer cells, as more fully described under the discussion of 'Technology' contained in the License.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 26530
License Grant
The Company signed a license agreement with the University for the exclusive rights of Mammastatin technology.
License Property
Mammastatin is a protein that has been found to be present in relatively higher levels in the breast tissue of healthy women as compared to those women that eventually have developed breast cancer.
Field of Use
The Comany developed the MSA test as a simple blood serum diagnostic that could measure the quantity of Mammastatin in blood serum using monoclonal antibody technology, whereby the results from that test could then be used to assess women’s risk of developing breast cancer.
IPSCIO Record ID: 5426
License Grant
Licensor grants, subject to the terms of this Agreement, to License a worldwide, perpetual and exclusive sublicense to make, use and sell the Protein and Antibodies solely for use with the Mammastatin Serum Assay and to make, have made, use and sell the Mammastatin Serum Assay and Improvements thereto.
Licensor grants, subject to the terms of this Agreement, to GBI a worldwide, perpetual and non-exclusive sublicense to make, use and create Improvements to Proteins and Antibodies solely in the research, development and sale of additional antibodies and/or diagnostic assays solely for the diagnosis of breast, prostate and/or ovarian cancers. Also includes to make, have made, use and create Improvements to the Mammastatin Serum Assay and the Know-How solely in the research, development and sale of Additional Products.
License Property
The Mammastatin Serum Assay is a test to measure Mammastatin levels in the serum of healthy women and breast cancer patients. This assay has been performed in two different formats with different antibody formats.
Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How
P&O TECHNOLOGY shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that BIOTHERAPIES cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.
IPSCIO Record ID: 4246
License Grant
Licensor grants, subject to the terms of this Agreement, to Licensee a worldwide, perpetual and exclusive license to make, have made, use and create improvements to the P&O Technology, Know-How and Improvements thereto to make, have made, use, market and sell Licensed Products.
License Property
Licensee shall have the right to grant sublicenses under the license granted herein.
Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How .
Field of Use
P&O Technology shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that Biotherapies cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.
IPSCIO Record ID: 4006
License Grant
The Licensor hereby grants the Licensee and its affiliates an exclusive, worldwide, perpetual, irrevocable, royalty-bearing License, with the right to grant and authorize subLicenses, under the Licensed Patents.
License Property
United States
Expiration
Patent 5,798,266
August 28, 2016
Patent 6,287,521
August 28, 2016
Patent 6,689,073
November 14, 2020
Patent 6,887,210
November 14, 2020
Patent 7,128,877
August 28, 2016
Patent Application 20060030787
Field of Use
The Licensee believes that these patents will allow the Licensee to develop the Mammary Aspirate Cytology Specimen Test (MASCT) System and the specialty laboratory ahead of any competition and will give it a competitive edge in the market.
IPSCIO Record ID: 372515
License Grant
Licensor of England grants to Licensee of Canada, an exclusive, worldwide license under the Licensed Patents to develop, make, have made, possess, utilize, sell, have sold and otherwise exploit the Licensed Products in the Territory.
License Property
Licensor is the owner of an invention, made at Licensor, relating to polymorphic epithelial mucin peptide in respect of which Licensor has made certain patent applications.
The New MUC1 Invention means any invention related and pertaining to
— MUC1 core protein peptide, polypeptide, protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof; and
— methods of making and using any MUC1 core protein peptide, polypeptide, protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof for the detection, evaluation, prevention and/or treatment of cancer.
Peptide means any peptide, polypeptide or protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof which is covered by a Valid Claim of the Licensed Patents.
Field of Use
The Field means the treatment or diagnosis of cancer.
IPSCIO Record ID: 383584
License Grant
Licensor grants a worldwide exclusive right and license under Know-how, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products.
Licensor grants an exclusive license under Patent Rights, with respect to Licensors fifty percent ownership interest in such Patent Rights, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products in all jurisdictions outside the United States.
License Property
Licensed Products shall mean Erbitux®, and matuzumab as well as all derivatives, analogs, fragments, improvements, conjugates and bioequivalents of any of the foregoing.
Erbitux® shall mean cetuximab, and marketed as Erbitux®.
ERBITUX (cetuximab) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a receptor found on both normal and tumor cells that is important for cell growth.
The patent is titled Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.
Field of Use
Erbitux ( cetuximab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
IPSCIO Record ID: 27645
License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.
Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5
4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas
5,286,647 – human-human hybridomas for neoplasms
5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.
5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.
6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions
6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
6,051,693 – CLNH11-specific antibodies
6,090,924 – human-human CLNH5-specific antibodies
6,165,467 – stabilized human monoclonal antibody preparation
Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.
The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
